PBM Capital Capitalizes GigaCyte
Blank Rome advised PBM Capital in the capitalization of, and acquisition of assets by, GigaCyte, a novel stem cell research and drug discovery company.
ABOUT PBM CAPITAL
PBM Capital Group, L.P. (PBM Capital) is a private investment firm primarily focused on private equity, publicly traded securities, and special opportunities. PBM Capital invests across all stages of corporate development including venture capital, leveraged buyouts, growth capital, distressed/turnaround, as well as public equity value investing. The firm creates long-term value by applying extensive industry knowledge and contacts, providing superior operational expertise, and bringing entrepreneurial spirit to attractive investment opportunities. The firm's investments span a range of industry sectors, including life sciences, specialty pharmaceutical, medical devices, health/wellness, and consumer products. PBM Capital creates revolutionary companies with innovative products that can change the world and improve the quality of people's lives.
ABOUT GIGACYTE
GigaCyte is a life science company providing novel human stem cell derived models for research and drug discovery. GigaCyte partners with key academic leaders and pharmaceutical industry leaders to develop new systems for drug discovery and to market products directly to the research and big pharma communities. The company has several model systems that provide first-in-class high content screening products to screen drug compounds prior to clinical studies. This disruptive technology provide big pharma with an "insurance policy" to quickly identify compounds that will be toxic to humans, potentially saving billions in the drug discovery process.